Investment Conclusion. On July 22, Puma Biotechnology (NYSE:PBYI) reported data from its ExteNET study on Neratinib in the adjuvant setting as 2nd year treatment following a full year of Herceptin therapy for HER2+ breast cancer. The data indicated 33% and 37% improvement over placebo for the overall and subgroup populations. However, the read out was missing DFS figures required to reach any conclusions on the strength of the results. In addition, in the HERA study that evaluated Herceptin as 2nd year treatment following a 1st full year of the drug, the DFS at 3 years follow up approached 89%. Therefore, Neratinib would have to handily beat that statistic for payors to reimburse the drug after a full year...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|